Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309834 | 0.80 | MAOB (0.40) | MAOBADORA3ARCYP19A1KDM4E | |
| SCHEMBL520027 | 0.71 | CA12 (0.41) | MAOBKDM4EHSD17B10PKMTSHR | |
| SCHEMBL3128 | 0.69 | — | — | |
| SCHEMBL2851479 | 0.69 | — | — | |
| SCHEMBL61449 | 0.68 | MAOA (0.54) | MAOBPKMTSHRMAOARAB9A | |
| SCHEMBL556071 | 0.67 | TDP1 (0.40) | MAOBADORA3ARCYP19A1KDM4E | |
| 3-Coumaranone SCHEMBL69412 | 0.67 | PKM (0.56) | MAOBADORA3ARCYP19A1KDM4E | |
| SCHEMBL4842874 | 0.67 | S100A4 (0.38) | MAOBKDM4EMAOANPC1RAB9A | |
| 3-Coumaranone SCHEMBL29420742 | 0.67 | PKM (0.56) | MAOBADORA3ARCYP19A1KDM4E | |
| SCHEMBL3352213 | 0.67 | MAOB (0.42) | MAOBADORA3ARCYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1829709-A | Bicyclic imidazol derivatives against flaviviridae | GENELABS TECH INC (US) | 2006-09-06 | — | — | CN | claimed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| WO-1998033382-A1 | FUNGICIDAL COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998023155-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0821677-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-04 | — | — | EP | claimed |
| WO-2024150222-A1 | IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME | MANA BIO LTD. (IL) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024134657-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIDAZINE BASED COMPOUNDS AND USE THEREOF AS PKR INHIBITORS | PROTEKT THERAPEUTICS LTD. (IL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024052923-A1 | IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME | BARCODE NANOTECH LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| EP-4326332-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | Biond Biologics Ltd. (IL) | 2024-02-28 | — | — | EP | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177187-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| WO-2000064888-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0836384-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| EP-0821677-A1 | OXAZOLINE AND THIAZOLINE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | MAOB 4822/4885ADORA3 4614/4885AR 40/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | MAOB 4606/4885ADORA3 4768/4885AR 3842/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | MAOB 660/4885ADORA3 1510/4885AR 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.